What Improvements Do We Need To See In Cell And Gene Supply Chains?

By George Todorov, MS, and Catherine Jomary, PhD

It is difficult to overstate the potential for emerging cell and gene therapies, yet we put lives at risk as supply chains remain vulnerable to disruption. Cell and gene therapies offer the first hope of truly curative treatment for several intractable diseases such as B cell malignancies, hemophilia, spinal muscular atrophy, ocular disease, and many other life-threatening rare diseases. As this industry segment grows, the global supply chain faces a menagerie of constraints exacerbated by geo-political issues and the COVID-19 pandemic. Learn about the supply of life-saving cell and gene therapies and what improvements are needed.